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Background: Leptomeningeal metastases (LM) are an increas-
ingly frequent and devastating complication of anaplastic lymphoma 
kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC). 
Currently, the optimal management of LM in ALK-positive patients 
remains poorly understood as these patients have been routinely 
excluded from clinical trials.
Methods: We describe four ALK-positive patients with LM who 
were treated with the next-generation ALK inhibitor alectinib through 
single-patient, compassionate use protocols at two institutions. All 
patients had previously been treated with both FDA-approved ALK 
inhibitors—crizotinib and ceritinib. Patients received alectinib at a 
starting dose of 600 mg twice daily.
Results: Four ALK-positive NSCLC patients with symptomatic 
leptomeningeal disease were identified. Three of four patients expe-
rienced significant clinical and radiographic improvements in LM 
upon treatment with alectinib. A fourth patient had stable intracra-
nial disease for 4 months before eventual systemic disease progres-
sion. Overall, alectinib was well tolerated. One patient required dose 
reduction due to grade 2 hyperbilirubinemia.
Conclusions: Alectinib is active in ALK-rearranged NSCLC patients 
with LM, including in patients previously treated with crizotinib and 
ceritinib. Additional prospective studies of alectinib in ALK-positive 
patients with LM are warranted.
Key Words: ALK, Anaplastic lymphoma kinase, Leptomeningeal 
metastases, Alectinib.
(J Thorac Oncol. 2015;10: 232–236)
Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non–small-cell lung can-
cer (NSCLC) that confer sensitivity to ALK tyrosine kinase 
inhibitors (TKIs).1,2 Crizotinib was the first ALK tyrosine 
kinase inhibitor approved for ALK-positive NSCLC based 
upon randomized studies demonstrating significant improve-
ments in objective response rates and progression-free sur-
vival compared with cytotoxic chemotherapy.3 Despite this 
activity, however, patients ultimately progress on therapy, at 
which time management approaches commonly include treat-
ment with second-generation ALK inhibitors (e.g., ceritinib, 
AP26113, and alectinib) or chemotherapy.
Recently, the central nervous system (CNS) has emerged 
as an important sanctuary site in ALK-positive NSCLC. 
Approximately 26% of ALK-positive patients with newly 
diagnosed, metastatic disease have CNS metastases.4 The inci-
dence of CNS metastases also appears to increase with dis-
ease course. For example, among crizotinib-treated patients 
enrolled on trials of second-generation ALK inhibitors, rates 
of CNS metastases have been as high as 60%.5 ALK-positive 
patients may also experience less common forms of CNS 
involvement, such as spinal cord intramedullary and lepto-
meningeal metastases (LM).6,7
Herein, we present a series of four ALK-positive 
NSCLC patients who developed LM on or after treatment with 
crizotinib and ceritinib, and were treated with the second-gen-
eration ALK inhibitor alectinib (CH5424802/RO5424802). 
Alectinib is a novel, highly potent and selective ALK inhibitor 
that has demonstrated promising antitumor activity in early 
phase trials.8
PATIENTS AND METHODS
Patients were treated with alectinib through single-
patient, compassionate use protocols at two institutions: 
Massachusetts General Hospital and the Medical University 
of South Carolina. All patients received alectinib at a start-
ing dose of 600 mg twice daily, which is the established 
recommended phase II dose.8 Consistent with prior reports, 
patients were considered to have LM if they had cyto-
logically confirmed malignant cells in cerebrospinal fluid 
(CSF) or gadolinium-enhanced magnetic resonance imag-
ing (MRI) consistent with LM (i.e., presence of abnormal 
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leptomeningeal enhancement or enhancing subarachnoid 
nodules).9
RESULTS
Case 1 involves a 56-year-old man with metastatic, 
ALK-rearranged NSCLC. A baseline MRI was negative for 
intracranial metastases. He was initially treated with crizo-
tinib, achieving a significant radiographic response. Sixteen 
months later, however, he developed osseous metastases and 
multiple new, asymptomatic brain parenchymal metastases. 
Radiation therapy was deferred in favor of treatment with 
the second-generation ALK inhibitor ceritinib. Despite sig-
nificant improvement of his systemic disease on ceritinib, 
repeat neuroimaging demonstrated progressive CNS dis-
ease, including new leptomeningeal enhancement. Soon 
thereafter, the patient experienced a generalized seizure, 
prompting treatment with corticosteroids and whole brain 
radiotherapy (WBRT). His post-radiation therapy course 
was complicated by persistent fatigue, word-finding dif-
ficulties and intermittent confusion. Ceritinib, which had 
been held throughout radiation, was resumed. Repeat neuro-
imaging 2 months later demonstrated interval improvement 
in numerous brain metastases, but unchanged leptomenin-
geal enhancement. The patient’s mental status and mobil-
ity continued to decline, ultimately prompting the transition 
to alectinib (600 mg twice daily). Within several weeks, he 
experienced significant improvements in cognition, energy, 
and mobility. Alectinib was well tolerated without signifi-
cant adverse events (AEs). Repeat imaging 2 months later 
demonstrated near complete resolution of leptomeningeal 
enhancement (Fig. 1) and stable systemic disease. The 
patient has remained on alectinib for 5 months with contin-
ued intracranial response.
Case 2 involves a 50-year-old man with metastatic 
ALK-positive NSCLC treated with first-line crizotinib. 
He initially responded to crizotinib, but developed grade 4 
transaminase elevation, ultimately prompting discontinua-
tion of therapy. He subsequently received carboplatin/peme-
trexed, maintenance pemetrexed, and ceritinib. Notably, a 
pre-ceritinib brain MRI revealed asymptomatic CNS paren-
chymal metastases, which initially improved on therapy. 
Repeat neuroimaging 7 months later, however, demonstrated 
innumerable new brain parenchymal metastases as well as 
leptomeningeal enhancement. He underwent radiosurgery 
(Gamma Knife) to multiple target lesions followed by even-
tual WBRT. Four months later, the patient developed left-
sided ptosis, diplopia, slurred speech, and headaches. Repeat 
imaging showed worsening LM, including new diffuse 
enhancement throughout the leptomeninges of the spine. 
Ceritinib was discontinued. He began alectinib in March 
2014. After 3 weeks of therapy, he had dramatic improve-
ments in headaches, speech, diplopia, and performance 
status. Repeat imaging 2 months later demonstrated signifi-
cant interval improvement in leptomeningeal enhancement 
throughout the neuraxis. No significant AEs were observed 
while on alectinib. After 6 months of therapy, however, the 
patient developed recurrent neurologic symptoms. Imaging 
confirmed progressive LM, as well as interval progression in 
the liver. He was ultimately transitioned to hospice and died 
in October 2014.
Case 3 involves a 39-year-old woman with metastatic, 
ALK-positive NSCLC initially treated with cisplatin/peme-
trexed (one cycle) followed by crizotinib. She remained on 
therapy with good systemic disease control until February 
2013, when a brain MRI revealed new left parietal dural 
enhancement with extension into the leptomeninges. She was 
treated with WBRT, resuming crizotinib upon completion. 
Two months later, she was found to have systemic disease pro-
gression with stable neuroimaging. She subsequently received 
ceritinib followed by carboplatin/pemetrexed/crizotinib. In 
August 2014, she developed headaches, right-sided weak-
ness, visual hallucinations and focal seizure activity. A brain 
MRI showed an enlarging left parietal leptomeningeal-based 
FIGURE 1.  T1, post-gadolinium 
magnetic resonance images (MRI) 
depicting near complete resolution 
of leptomeningeal enhancement in a 
patient treated with alectinib. A, Before 
treatment with alectinib (blue arrows 
abnormal leptomeningeal enhance-
ment). B, Two months after initiation 
of treatment with alectinib.
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lesion with extension of LM enhancement (Fig. 2). She was 
placed on corticosteroids and levetiracetam. Intrathecal che-
motherapy was deferred due to its unclear efficacy in large 
nodular dural-based disease. She began alectinib 600 mg 
twice daily. She tolerated alectinib well with no significant 
treatment-related AEs. Her right-sided weakness gradually 
improved and her seizures resolved, and her corticosteroids 
were tapered off. After 6 weeks of alectinib, repeat neuroim-
aging demonstrated significant interval reduction in nodular 
dural-based and LM enhancement. The patient remains on 
alectinib at this time with no evidence of progression in her 
CNS disease.
Case 4 involves a 49-year-old woman diagnosed with 
stage IIA (T2bN0M0) NSCLC in February 2013. She under-
went surgical resection and 4 cycles of adjuvant cisplatin/
pemetrexed. On October 2013, she developed pulmonary 
nodules and a pleural effusion, consistent with recurrent 
disease. ALK FISH performed on her resection specimen 
revealed an ALK rearrangement. She began treatment with 
crizotinib. Of note, a brain MRI performed shortly after start-
ing crizotinib was negative for intracranial metastases. She 
remained on crizotinib for 7 months, transitioning to ceri-
tinib upon disease progression. After 1 month of ceritinib, 
she required hospitalization for worsening fatigue, dyspnea, 
and dysgeusia. Brain MRI revealed innumerable brain 
parenchymal metastases with leptomeningeal involvement. 
Ceritinib was discontinued. She was started on corticoste-
roids and experienced an improvement in her fatigue and per-
formance status. Upon discharge, she began alectinib 600 mg 
twice daily. Treatment was briefly interrupted due to grade 2 
hyperbilirubinemia, which required dose reduction to 450 mg 
twice daily. Her CNS disease remained stable over the next 4 
months; however, she ultimately developed disease progres-
sion in the chest.
DISCUSSION
LM in NSCLC have been historically associated with 
a dismal prognosis (median survival 3.0–4.3 months).10,11 
Importantly, patients with LM have been routinely excluded 
from clinical trials; thus, data on management largely 
comes from retrospective analyses involving heterogeneous 
patient populations. Common treatment strategies have 
included WBRT, intrathecal or systemic chemotherapy, and 
palliative ventriculoperitoneal shunting. Among NSCLC 
patients with EGFR mutations, “pulsatile” EGFR inhibition 
has also been explored, and data suggests that this achieves 
higher CSF drug concentrations, controlling LM in a subset 
of patients.12
In ALK-positive NSCLC, LM is present in approxi-
mately 4% of patients,6 but the optimal management of 
this complication is poorly defined. Early studies focused 
on the use of crizotinib, which has been associated with a 
12-week intracranial disease control rate of 56% in patients 
with untreated brain parenchymal metastases; however, only 
7% of patients have objective intracranial responses.13 It 
has also been recognized that the CNS is a frequent site of 
relapse on crizotinib, commonly in the setting of continued 
systemic disease control—likely reflecting a pharmacoki-
netic failure of therapy. Indeed, in one case report, the CSF-
to-plasma ratio of crizotinib was very low (0.0026) in a 
patient following crizotinib administration, suggesting poor 
blood–brain barrier penetration.14 Investigators have since 
explored using high-dose crizotinib (1000 mg once daily) 
or high-dose crizotinib (600 mg once daily) plus peme-
trexed (900 mg/m2) in patients with brain metastases, but 
such reports were small and did not include patients with 
LM.15,16 Crizotinib has also been combined with intrathecal 
methotrexate in one report, producing cytological responses 
in two patients with LM; however, the relative contributions 
of crizotinib versus methotrexate on treatment effects in this 
series were unclear.7
Given crizotinib’s limited CNS activity, emphasis 
has been placed on identifying new ALK inhibitors with 
improved CNS penetration. Here, we report a series of four 
ALK-positive patients with LM who experienced clinical 
benefit on alectinib. All four patients were diagnosed with 
LM based on characteristic MRI features and symptoms. 
Although CSF cytology has been considered the histori-
cal gold standard for LM, it has low sensitivity.17 Contrast-
enhanced MRI, with its improved visualization of the 
subarachnoid space, is now considered sufficient to establish 
the diagnosis in a patient with typical clinical features and 
has become the initial, and frequently sole, diagnostic tool.9,18 
Impressively, three of four patients with LM experienced 
radiographic and clinical improvement, whereas a fourth had 
stable imaging findings. In animal models, alectinib shows 
FIGURE 2.  Regression of a nodular 
leptomeningeal metastasis in an ALK-
positive patient treated with alectinib. 
Sagittal, T1 post-gadolinium magnetic 
resonance images A, before treatment 
with alectinib (blue arrows abnormal, 
nodular leptomeningeal enhancement) 
and B, 6 weeks after starting alectinib.
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high brain-to-plasma ratios (0.63–0.94) and activity in intra-
cranial tumor implantation models.19 In contradistinction to 
crizotinib and ceritinib,20 preclinical studies also suggest that 
alectinib is not a substrate of P-glycoprotein (P-gp), a key 
drug efflux pump typically expressed in the blood–brain bar-
rier.19 Clinically, objective responses have been seen in 55% 
of crizotinib-resistant/intolerant patients treated with alec-
tinib in an ongoing phase I/II trial.8 Importantly, among 21 
patients with baseline CNS lesions in this study, 52% had 
objective responses in the CNS. Moreover, measurable con-
centrations of alectinib were found in 5 of 5 patients who 
underwent CSF sampling, confirming the CNS penetration 
of alectinib.
In addition to alectinib, data on the CNS activity of other 
next-generation ALK inhibitors has recently emerged. For 
example, in an ongoing phase I/II trial of the ALK inhibitor 
AP26113, 10 of 14 patients (71%) with untreated/progressive 
brain metastases experienced intracranial tumor regressions 
on therapy.21 CNS antitumor activity has also been described 
with ceritinib. Specifically, intracranial responses were seen in 
10 of 29 patients (34.5%) who entered the phase I study of ceri-
tinib with measurable CNS metastases.22 More recently, radio-
graphic improvements were also reported in an ALK-positive 
patient with LM who was treated with ceritinib.23 However, 
as illustrated by this report, patients may relapse in the CNS 
despite treatment with ceritinib. Indeed, CNS concentrations 
of ceritinib are predicted to be approximately 15% of plasma 
levels based upon animal models.24 It is therefore possible that 
the CNS activity of alectinib in this series may have been due 
to enhanced CNS bioavailability, thereby overcoming incom-
plete ALK inhibition.
In summary, we demonstrate that alectinib has sig-
nificant antitumor activity in ALK-positive patients with 
LM. Moreover, alectinib was active in this cohort despite 
prior exposure to both crizotinib and ceritinib (the two 
ALK inhibitors currently approved by the FDA), suggest-
ing that alectinib may have greater CNS activity. Of note, 
in addition to responses among these patients with LM, we 
have also observed antitumor activity in brain parenchymal 
metastases in a patient treated with compassionate use alec-
tinib after CNS relapses on crizotinib and ceritinib (Fig. 3). 
Additional prospective studies of alectinib in ALK-positive 
patients with CNS metastases, including LM, are there-
fore warranted. Indeed, one such study, the ALEX study, is 
already ongoing. This phase III randomized trial is evaluat-
ing first-line crizotinib versus alectinib in treatment-naive, 
FIGURE 3.  Marked regression in brain 
parenchymal metastases in a 46-year-old, 
ALK-positive lung cancer patient treated 
with alectinib. This patient had previously 
received both crizotinib and ceritinib, relaps-
ing in the central nervous system after each 
agent. Axial, T1 post-gadolinium magnetic 
resonance images A) before alectinib and B) 
on alectinib.
TABLE 1.  Baseline Characteristics of ALK-Positive Patients with Leptomeningeal Metastases
Pt. Age Sex
Prior ALK 
Inhibitors
Previous Radiation 
Therapy
Interval from 
Diagnosis to 
Development of LM
Concomitant 
Brain Metastases Neurologic Symptoms
1 56 M Crizotinib, ceritinib WBRT 23 Months Yes Seizure, confusion, word-finding 
difficulties
2 50 M Crizotinib, ceritinib Radiosurgery × 2, 
WBRT
18 Months Yes Headaches, diplopia, slurred 
speech, nausea, ptosis
3 39 F Crizotinib, ceritinib WBRT 9 Months No Focal seizures, right-sided 
weakness, visual hallucinations
4 49 F Crizotinib, ceritinib None 16 Months Yes Fatigue
ALK, anaplastic lymphoma kinase; F, female; LM, leptomeningeal metastases; M, male; WBRT, whole brain radiation therapy.
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ALK-positive lung cancer patients (NCT02075840). Of 
note, the ALEX trial permits patients with asymptomatic 
brain or LM to enroll. Moreover, time to CNS progression 
is a key secondary endpoint of the study, which may in turn 
provide important prospective data on the CNS antitumor 
activity of both agents.
As is common with targeted therapies in NSCLC, 
acquired resistance developed in two patients in this series, 
highlighting the need for additional therapies or therapeutic 
combinations with activity in the CNS. One approach has been 
to use still more potent and/or structurally distinct ALK inhib-
itors. For example, PF-06463922 is a novel ALK inhibitor that 
was recently developed and rationally designed to minimize 
P-gp-mediated drug efflux and optimize CNS penetration.25 
In preclinical models, this agent has shown antitumor activity 
in the CNS and has demonstrated strong activity against all 
known ALK resistance mutations identified in patients with 
crizotinib-resistant disease. Moving forward, clinical trials of 
novel, brain penetrable targeted therapies may help inform the 
optimal management of CNS metastases in advanced ALK-
positive NSCLC.
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